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OBJECTIVES: Lipodystrophy (LD) impacts QoL of HIV patients. Facial lipoatrophy 
(FL) is particularly stigmatizing. Patient Reported Outcomes measures (PROs) are not 
often used as a primary endpoint to measure interventions speciﬁc to LD. The aim of 
this study was to evaluate the QoL (primary endpoint) and other endpoints of HIV 
patients treated for FL by poly-L-lactic acid (PLLA) injection. METHODS: 245 
patients with FL were included in an open label prospective study and treated with 1 
to 5 treatment sessions at monthly intervals. Speciﬁc PROs were evaluated by the 
Assessment of Body Change and Distress (ABCD), including: QoL (21 items with 4 
domains, 0–100 scale), signs of LD (6 items, 0–6 point scale), and global satisfaction 
(1 item, 1–5 point scale) at baseline and 2 months after the last injection. The Overall 
Treatment Effect (OTE) (scale from 7 to  7) was also assessed at this date. Photo-
graphs were evaluated, blind by experts using James’ grading (1–4, 4 being severe FL). 
RESULTS: 191 patients completed the questionnaires. Mean age was 48 o 8 years, 
87% men, with FL since 5 o 3 years. The mean number of treatment sessions was 4 
o 1.3. The QoL global score improved signiﬁcantly by 13,5 points (24 %, p  0,001) 
and each of 4 domains improved: Satisfaction with the appearance 14,7 points; Psy-
chosocial impact 15,4; Fear of Future 10,5 and Relation with HAART 4,1. Global 
satisfaction improved from 2,6 to 3,3. Score of LD signs improved from 3,3 to 2,2. 
The OTE improved by 5,3 o 1.5 points. Photographs’ grading improved by 1.2 o 0.7 
points. All results were signiﬁcant (p  0,001). QoL score and Photo’s grading were 
not signiﬁcantly associated. CONCLUSIONS: QoL for people with FL improved sig-
niﬁcantly after PLLA injection. However, a modest correlation between PRO’s and 
photographs suggest that PRO’s are important endpoints in LD management 
interventions.
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OBJECTIVES: Prior to use in an international clinical trial in 15 countries involving 
individuals suffering from HIV, the 87-item HIV PATIENT SYMPTOMS PROFILE 
(HPSP), underwent linguistic validation in 21 languages to ensure conceptual equiva-
lence, cultural relevance and harmonisation across languages. Special care had to be 
taken when producing the 5 translations for Israel (Arabic, Amharic, English, Hebrew    
and Russian) to adequately address the nuances associated with the diverging cultural           
heritage of these languages. METHODS: The following standardized methodology    
was employed: after a deﬁnition of the original concepts by the developer, the transla-
tion process was coordinated by a specialist for each target language involving the 
following steps: 1) two forward translations by professional translators, native speak-
ers of the target language and ﬂuent in English; 2) comparison and reconciliation of 
the translations; 3) backward translation by a native English speaker; 4) comparison 
of source and backward version; and (5) comprehension test on 6 HIV patients for 
each language. RESULTS: Linguistic and conceptual issues emerged during the trans-       
lation process in Israel, when addressing the issues outlined above. The most recurrent   
challenge was the absence of words in the target languages for speciﬁc concepts 
described in the English original. The translations had to resort to paraphrases and 
descriptions to provide the most appropriate approximation of the original notion 
in the target languages. Examples and their solutions will be described in the pre-
sentation. CONCLUSIONS: The 5 languages for Israel were produced according to         
a rigorous methodology to ensure conceptual equivalence, cultural relevance and 
harmonisation across countries whilst addressing the speciﬁc challenges of multiple 
languages spoken in one country. The rigorous methodology used to translate the 
HPSP will be necessary for the future psychometric analyses once international data 
are obtained for this instrument.
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OBJECTIVES: Assessment of length of stay and patient ﬂow pathway of patients after 
admitted to Critical Care (Intensive Care Units [ICUs] or High-Dependency Units 
[HDUs]) with Pneumonia. METHODS: The analysis is based on inpatient hospital 
admission data from the National Health Service (NHS)’s Hospital Episode Statistics 
(HES) Database for England in 2005–2006. The study analysed patients admitted to 
an ICU with a primary or secondary diagnosis of Pneumonia. The bed days of and 
the destination of patients after the ﬁrst ICU stay (i.e. where the patients had not previ-
ously been admitted to Critical Care with Pneumonia in the same inpatient spell, based 
on the period from date of admission to date of discharge from hospital or death) 
formed the primary analysis. The same analysis for those patients moving to an HDU 
after their ﬁrst ICU stay was conducted. RESULTS: In 2005–2006, 838 ICU stays that 
met the criteria were identiﬁed. The average bed days for the ﬁrst ICU stay for patients 
with Pneumonia was 11.0 days (standard deviation [SD] 11.7 days). Of the patients 
in ICU with Pneumonia, 19.2% died. Of the remaining patients (where the destination 
data was recorded), 31.1% were moved to an HDU unit (same hospital), 67.7% 
moved to a non-critical ward (same hospital) and 1.2% were directly discharged from 
hospital. Of those patients that were moved into an HDU unit, the average bed days 
was 5.0 days (SD 5.7 days). At the end of their HDU stays, based on the destination 
data recorded, 75.9% were moved to a non-critical ward (same hospital), 21.7% were 
back to an ICU unit and 2.4% were discharged. Overall, the length of stay in hospital 
for patients with Pneumonia treated in critical care was, on average, 24.8 days 
(SD 23.2 days). CONCLUSIONS: At the end of the ﬁrst ICU stay with Pneumonia, 
19.2% died.
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OBJECTIVES: To determine the least costly immunization strategy, with or without 
screening for antibodies, against hepatitis A, hepatitis B, varicella, measles and tetanus 
in Catalonia, Spain. METHODS: The least costly immunization strategy for each 
vaccine in different age groups was determined using: 1) the prevalence of protected 
individuals (positive results), called p, observed in serological surveys in Catalonia and 
2) the critical prevalence of antibodies, called p*, that makes cost-effectiveness of 
vaccinating all individuals equal to screening and vaccination of susceptibles. Vacci-
nating all individuals was less costly than screening and vaccination when the preva-
lence of protected individuals was lower than p*. A formula to estimate p* was derived 
from the cost-effectiveness equations. RESULTS: The value of p* depended on screen-
ing and vaccination costs, programme compliance, screening test performance, vaccine 
efﬁcacy and disease costs. The following values of p* were obtained: 22.5 % for hepa-
titis A, 26.7 % for hepatitis B, 12.0 % for varicella, 100 % for measles and tetanus 
in adults, and 32.7 % for hepatitis A, 43.9 % for hepatitis B, 22.8 % for varicella, 
100 % for measles and tetanus in individuals aged 5–14 years. Based on these results 
and the prevalence of protected individuals observed in the population (p) in serologi-
cal surveys, the least costly immunization strategy was vaccination without screening 
for hepatitis B, measles and tetanus at all ages and for hepatitis A in adolescents, since 
p  p*, and screening and vaccination of susceptibles for varicella at all ages and 
for hepatitis A in adults, since p  p*. CONCLUSIONS: Immunization programmes 
should be developed taking into account the prevalence of protected individuals and 
the critical prevalence of antibodies to reduce costs.
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OBJECTIVES: This study focuses on the health economical impact of new malaria 
diagnostic devices on the Malaria control processes in Brazil. Current diagnostic tools 
have disadvantages which prevent the total coverage of malaria risk regions. As a 
consequence, there is a high demand for diagnostic devices that can be used in remote 
settings. The objective of this research is to study the cost-effectiveness of new diag-
nostic devices. METHODS: Markov modeling and Monte Carlo simulation are used 
to compare the expected cost-effectiveness of the new devices Magneto-Optic Technol-
ogy (MOT), Rapid Diagnostic Tests (RDT), and Software Aided Microscopy (SAM), 
with the golden standard of microscopy. Outcome measures are the diagnostic and 
treatment costs as well as deaths avoided. Scenario analysis is used to compare differ-
ent implementation strategies of the devices that are expected to be or become most 
cost-effective. RESULTS: Microscopy has the highest cost-effectiveness ratio (1.78), 
followed by SAM (4.02). The access of Microscopy to remote risk regions is however 
limited. The implementation scenario with the highest health economic impact is to 
apply microscopy and to use in addition SAM in remote risk regions. At a total of 80 
per cent access to diagnosis, microscopy combined with SAM saves in Brazil up to 
36.000 lives (30 % improvement) with a cost-saving of 6 M (26 per cent savings). 
CONCLUSIONS: The outcomes provide clear guidelines for the investment in new 
devices. Accordingly, Markov modeling is a valuable tool for medical industry facing 
decisions concerning technology development and implementation.
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OBJECTIVES: The objective of this study was to estimate the national prevalence, 
mortality, and cost of CLABSIs. CLABSI prevalence in ICUs has been studied in a few 
hospitals, and some states mandate reporting selected blood stream infections (BSI), 
